Cardiovascular Risk in Patients with COPD: Cardiovascular Comorbidities in Patients with COPD Increase CAT and mMRC Dyspnea Scores
DOI:
https://doi.org/10.3889/oamjms.2021.7942Keywords:
Chronic obstructive pulmonary disease, Cardiovascular comorbidity, DyspneaAbstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with a number of different comorbidities. Cardiovascular diseases (CVD) are the most frequent comorbidities in COPD. The economic burden associated with cardiovascular comorbidity (CVC) in this population of patients is considerable. The COPD patients are related to the increased systemic inflammation, reduced capacity for physical activity, and airflow obstruction.
AIM: The aim of our investigation was to evaluate the dyspnea as a disabling symptom in COPD patients with cardiovascular comorbidity (CVC) especially heart failure. The main aim of this study is to evaluate its intensity in patients with COPD in stages II according to GOLD.
METHODS: The investigation was conducted from December 2019 to January 2020, on pulmonology and allergology clinic and cardiology clinic of medical faculty in Skopje. We investigated 65 outpatients with COPD, 44 with different type of CVD, Group I, and 21 without CVD, Group II. All patients were with partial chronic respiratory failure (In type 1 respiratory failure hypoxemic). Patients, according GOLD initiative, were in COPD stadium II, 70% < forced expiratory volume in 1 s (FEV1)>50%. Heart condition was diagnosed on the basis of clinical examination, electrocardiography, and echocardiography of the heart. Included patients with CVD were with ejection fraction (EF) <65%. Dyspnea was measured with modified MRC (mMRC) dyspnea scale.
RESULTS: The forced vital capacity and forced expiratory volume in 1 s were statically significantly higher in Group II with CVD. Dyspnea measured with Modified Medical Research Council (MRC) dyspnea scale showed statistically significantly higher values in Group I COPD patients with CVC (2.9 ± 1.4) versus Group II without CVC (1.7 ± 1.4), (p < 0.05). The perception of the higher dyspnea in Group I was associated with increased COPD assessment test-scores, in Group I: Group I (19.8 ± 9.1) versus Group II: (9.8 ± 9.1), (p < 0.001). The number of exacerbations and what is more important the number of severe exacerbation leading to hospitalizations was statistically higher in patients of Group I with CVC than in Group II without CVC (3.0 ± 1.1 vs. 1.0 ± 2.1), (p < 0.001) and the number of hospitalizations (1.0 ± 1.1 vs. 0.3 ± 2.1) (p < 0.001).
CONCLUSION: We can conclude that patients with COPD who have CVC have an increased risk of high symptoms, which mean poor quality of life and increased morbidity.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Gold Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD; 2019. Available from: http://www.goldcopdorg/guidelines-global-strategy-for-diagnosis-managementhtml.2020 [Last accessed: 2021 May 25].
van Remoortel H, Hornikx M, Langer D, Burtin C, Everaerts S, Verhamme P, et al. Risk factors and comorbidities in the pre-clinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;189(1):30-8. https://doi.org/10.1164/rccm.201307-1240OC PMid:24219412 DOI: https://doi.org/10.1164/rccm.201307-1240OC
Aisanov Z, Khaltaev N. Management of Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease Patients. WHO Global Coordination Mechanism for NCD Prevention and Control. Vol. 12. Geneva, Switzerland: World Health Organization; 2020. DOI: https://doi.org/10.21037/jtd.2020.03.60
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-85. https://doi.org/10.1183/09031936.00128008 PMid:19407051 DOI: https://doi.org/10.1183/09031936.00128008
Vonk Noordegraaf A, Marcus JT, Roseboom B, Postmus PE, Faes TJ, de Vries PM. The effect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary emphysema. Chest 1997;112:640-5. https://doi.org/10.1378/chest.112.3.640 PMid:9315795 DOI: https://doi.org/10.1378/chest.112.3.640
O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: Mechanical factors. COPD. 2007;4(3):225-36. https://doi.org/10.1080/15412550701480455 PMid:17729066 DOI: https://doi.org/10.1080/15412550701480455
Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540. https://doi.org/10.1371/journal.pone.0085540 PMid:24427316 DOI: https://doi.org/10.1371/journal.pone.0085540
Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of dyspnea. Dtsch Arztebl Int. 2016;113(49):834-45 https://doi.org/10.3238/arztebl.2016.0834 PMid:28098068 DOI: https://doi.org/10.3238/arztebl.2016.0834
Cherian M, Jensen D, Tan WC, Mursleen S, Goodall EC, Nadeau GA, et al. Dyspnoea and symptom burden in mild-moderate COPD: The Canadian cohort obstructive lung disease study. ERJ Open Res. 2021;7(2):00960-2020. https://doi.org/10.1183/23120541.00960-2020 PMid:33898621 DOI: https://doi.org/10.1183/23120541.00960-2020
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-6. https://doi.org/10.1136/thx.54.7.581 PMid:10377201 DOI: https://doi.org/10.1136/thx.54.7.581
Giezeman M, Hasselgren M, Lisspers K, Ställberg B, Montgomery S, Janson C, et al. Influence of comorbid heart disease on dyspnea and health status in patients with COPD-a cohort study. J Chron Obstruct Pulmon Dis. 2018;13:3857-65. https://doi.org/10.2147/COPD.S175641 PMid:30568437 DOI: https://doi.org/10.2147/COPD.S175641
Janson C, Marks G, Buist S, Gnatiuc L, Gislason T, McBurnie MA, et al. The impact of COPD on health status: Findings from the BOLD study. Eur Respir J. 2013;42(6):1472-83 https://doi.org/10.1183/09031936.00153712 PMid:23722617 DOI: https://doi.org/10.1183/09031936.00153712
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, i. An official American thoracic society statement: Update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-52. https://doi.org/10.1164/rccm.201111-2042ST PMid:22336677 DOI: https://doi.org/10.1164/rccm.201111-2042ST
Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;12(12):CD011594. https://doi.org/10.1002/14651858.CD011594.pub2 PMid:305365667 DOI: https://doi.org/10.1002/14651858.CD011594.pub2
Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T. Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(9):841-6. https://doi.org/10.1053/rmed.2000.0804 PMid:11001074 DOI: https://doi.org/10.1053/rmed.2000.0804
Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;198(9):1130-9. https://doi.org/10.1164/rccm.201804-0621CI PMid:29979608 DOI: https://doi.org/10.1164/rccm.201804-0621CI
Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011;20:15-22. https://doi.org/10.4104/pcrj.2010.00060 PMid:20871945 DOI: https://doi.org/10.4104/pcrj.2010.00060
Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101(3):353-8. https://doi.org/10.1016/j.amjcard.2007.08.046 PMid:18237599 DOI: https://doi.org/10.1016/j.amjcard.2007.08.046
O’Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: New mechanistic insights and management implications. Adv Ther. 2020;37(1):41-60. https://doi.org/10.1007/s12325-019-01128-9 PMid:31673990 DOI: https://doi.org/10.1007/s12325-019-01128-9
Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006;119(10):21-31. https://doi.org/10.1016/j.amjmed.2006.08.004 PMid:16996896 DOI: https://doi.org/10.1016/j.amjmed.2006.08.004
Antoniu SA. Descriptors of dyspnea in obstructive lung diseases. Multidiscip Respir Med. 2010;5(3):216-9. https://doi.org/10.1186/2049-6958-5-3-216 PMid:22958466 DOI: https://doi.org/10.1186/2049-6958-5-3-216
Vicent L, Olarte JM, Puente-Maestu L. Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases. BMC Palliat Car. 2017;16(1):35. https://doi.org/10.1186/s12904-017-0208-x PMid:28532487 DOI: https://doi.org/10.1186/s12904-017-0208-x
Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular comorbidities in chronic obstructive pulmonary disease (COPD)-current considerations for clinical practice. J Clin Med. 2019;8(1):69. https://doi.org/10.3390/jcm8010069 PMid:30634565 DOI: https://doi.org/10.3390/jcm8010069
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. UPLIFT investigators. Lancet. 2009;374(9696):1171-8. https://doi.org/10.1016/S0140-6736(09)61298-8 PMid:19716598 DOI: https://doi.org/10.1016/S0140-6736(09)61298-8
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al, TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89. https://doi.org/10.1056/NEJMoa063070 PMid:17314337 DOI: https://doi.org/10.1056/NEJMoa063070
Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ, et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-9. https://doi.org/10.1093/eurjhf/hfn013 PMid:19168510 DOI: https://doi.org/10.1093/eurjhf/hfn013
Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640-6. https://doi.org/10.1378/chest.128.4.2640 PMid:16236937 DOI: https://doi.org/10.1378/chest.128.4.2640
Sidney S, Sorel M, Quesenberry CP Jr., DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068-75. https://doi.org/10.1378/chest.128.4.2068 PMid:16236856 DOI: https://doi.org/10.1378/chest.128.4.2068
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Jagoda Stojkovic, Emilija Antova, Dragana Stojkovikj (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
